Why the study?
Understanding of heart failure with mid-range ejection fraction remains limited, particularly among Asian patients.
Do clinical characteristics and 1-year prognosis differ between HFmrEF, HFrEF, and HFpEF in Chinese patients?
Do clinical characteristics and 1-year prognosis differ between HFmrEF, HFrEF, and HFpEF in Chinese patients?
HFmrEF is a distinct clinical subgroup characterized by a high prevalence of ischemic heart disease and better 1-year survival compared to HFrEF.
No takes yet. Share an insight, caveat, or question.
HFmrEF may warrant phenotype-specific risk stratification in Asian cohorts; leaves open long-term outcomes and therapy trials.
Lyu et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: